



Market Announcement

6 July 2022

Neurotech International Limited (ASX: NTI) – Suspension from Official Quotation

Description

The securities of Neurotech International Limited ('NTI') will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder.

Issued by

Nikki Ciavatta
Adviser, Listings Compliance (Perth)

6 July 2022

Barbara Lim
Adviser, Listing Compliance (Perth)
Australian Securities Exchange
Level 40, Central Park
152 St Georges Terrace
Perth WA 6000
BY EMAIL: Barbara.lim@asx.com.au, tradinghaltsp Perth@asx.com.au

Dear Barbara Lim

Request for Voluntary Suspension

Neurotech International Limited (ASX: NTI) ('Company') requests that a voluntary suspension be placed on its securities.

The Company advises that:

- a) it is seeking a voluntary suspension pending an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. ("Announcement");
- b) the Company wishes the voluntary suspension to remain in place until such time as the Announcement is released to the market, or until the commencement of trade on Thursday 7 July 2022; and
- c) the Company is not aware of any reason why its request for a voluntary suspension should not be granted.

This request has been authorised by the Chairman of Neurotech International Limited.

Yours Faithfully,



Brian Leedman
Chairman